However, it would seem logical that patients who are biopsied have the most clinically significant disease, consistent with standard international practice.52 Furthermore, although our data capture is robust, data that are now indispensable in risk stratification for treatment of certain diseases, such as Oxford scores in IgA nephropathy, or phospholipase A2 receptor (PLA2R) antibody status in membranous nephropathy, are not available for many patients owing to their time of implementation in clinical care. This evidence concerns the gene PLA2R1 and IgA glomerulonephritis.